Tags

Type your tag names separated by a space and hit enter

Anti-GPC3 Antibody Tagged Cationic Switchable Lipid-Based Nanoparticles for the Co-Delivery of Anti-miRNA27a And Sorafenib in Liver Cancers.
Pharm Res 2019; 36(10):145PR

Abstract

PURPOSE

The immediate plasma metabolism and development of chemo-resistance (single agent) severely hampers the clinical effectiveness of Sorafenib (SRF) in liver cancer therapy. MicroRNA27a inhibition is a promising biological strategy for breast cancer therapy.

METHODS

In this study, we aimed to prepare SRF and anti-miRNA27a-loaded anti-GPC3 antibody targeted lipid nanoparticles to enhance the therapeutic efficacy against liver cancers. In this study, we have employed a unique cationic switchable lipid (CSL) as a mean to encapsulate miRNA as well as to confer pH-responsiveness to the nanocarrier system.

RESULTS

The G-S27LN was nanosized and offered a pH-responsive release of SRF from the carrier system and we have demonstrated the specific affinity of G-S27LN towards the GPC3-overexpressed HepG2 cancer cells. Anti-microRNA27a significantly increased the protein expression of FOXO1 and PPAR-γ which are crucial components involved in proliferation and apoptosis of tumor cells. Combination of SRF and anti-miRNA27a (G-S27LN) resulted in significantly lower cell viability with a marked increase in the apoptosis cell proportion compared to that of free SRF indicating the synergistic anticancer effect. Animal studies in liver cancer xenograft model demonstrated significant suppression of tumor burden, reduced tumor cell and elevated TUNEL positive apoptosis with no toxicity concerns in animals treated with G-S27LN formulation.

CONCLUSION

The CSL-based G-S27LN efficiently co-delivered anti-microRNA27a and SRF and therefore represents a promising therapy to treat liver cancer. This study also brings forth a platform strategy for the effective treatment of number of other advanced cancers.

Authors+Show Affiliations

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. AlissonAguirretpt@yahoo.com.Department of Hepatobiliary Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.Department of Hepatobiliary Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.Department of Hepatobiliary Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.Department of Hepatobiliary Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31396764

Citation

Wang, Zhengfeng, et al. "Anti-GPC3 Antibody Tagged Cationic Switchable Lipid-Based Nanoparticles for the Co-Delivery of Anti-miRNA27a and Sorafenib in Liver Cancers." Pharmaceutical Research, vol. 36, no. 10, 2019, p. 145.
Wang Z, Zhao K, Zhang Y, et al. Anti-GPC3 Antibody Tagged Cationic Switchable Lipid-Based Nanoparticles for the Co-Delivery of Anti-miRNA27a And Sorafenib in Liver Cancers. Pharm Res. 2019;36(10):145.
Wang, Z., Zhao, K., Zhang, Y., Duan, X., & Zhao, Y. (2019). Anti-GPC3 Antibody Tagged Cationic Switchable Lipid-Based Nanoparticles for the Co-Delivery of Anti-miRNA27a And Sorafenib in Liver Cancers. Pharmaceutical Research, 36(10), p. 145. doi:10.1007/s11095-019-2669-5.
Wang Z, et al. Anti-GPC3 Antibody Tagged Cationic Switchable Lipid-Based Nanoparticles for the Co-Delivery of Anti-miRNA27a and Sorafenib in Liver Cancers. Pharm Res. 2019 Aug 8;36(10):145. PubMed PMID: 31396764.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Anti-GPC3 Antibody Tagged Cationic Switchable Lipid-Based Nanoparticles for the Co-Delivery of Anti-miRNA27a And Sorafenib in Liver Cancers. AU - Wang,Zhengfeng, AU - Zhao,Kun, AU - Zhang,Yingxuan, AU - Duan,Xinxin, AU - Zhao,Yongfu, Y1 - 2019/08/08/ PY - 2019/05/04/received PY - 2019/07/08/accepted PY - 2019/8/10/entrez PY - 2019/8/10/pubmed PY - 2019/9/13/medline KW - anti-microRNA27a KW - apoptosis KW - lipid nanoparticles KW - liver cancer KW - sorafenib SP - 145 EP - 145 JF - Pharmaceutical research JO - Pharm. Res. VL - 36 IS - 10 N2 - PURPOSE: The immediate plasma metabolism and development of chemo-resistance (single agent) severely hampers the clinical effectiveness of Sorafenib (SRF) in liver cancer therapy. MicroRNA27a inhibition is a promising biological strategy for breast cancer therapy. METHODS: In this study, we aimed to prepare SRF and anti-miRNA27a-loaded anti-GPC3 antibody targeted lipid nanoparticles to enhance the therapeutic efficacy against liver cancers. In this study, we have employed a unique cationic switchable lipid (CSL) as a mean to encapsulate miRNA as well as to confer pH-responsiveness to the nanocarrier system. RESULTS: The G-S27LN was nanosized and offered a pH-responsive release of SRF from the carrier system and we have demonstrated the specific affinity of G-S27LN towards the GPC3-overexpressed HepG2 cancer cells. Anti-microRNA27a significantly increased the protein expression of FOXO1 and PPAR-γ which are crucial components involved in proliferation and apoptosis of tumor cells. Combination of SRF and anti-miRNA27a (G-S27LN) resulted in significantly lower cell viability with a marked increase in the apoptosis cell proportion compared to that of free SRF indicating the synergistic anticancer effect. Animal studies in liver cancer xenograft model demonstrated significant suppression of tumor burden, reduced tumor cell and elevated TUNEL positive apoptosis with no toxicity concerns in animals treated with G-S27LN formulation. CONCLUSION: The CSL-based G-S27LN efficiently co-delivered anti-microRNA27a and SRF and therefore represents a promising therapy to treat liver cancer. This study also brings forth a platform strategy for the effective treatment of number of other advanced cancers. SN - 1573-904X UR - https://www.unboundmedicine.com/medline/citation/31396764/Anti-GPC3_Antibody_Tagged_Cationic_Switchable_Lipid-Based_Nanoparticles_for_the_Co-Delivery_of_Anti-miRNA27a_And_Sorafenib_in_Liver_Cancers L2 - https://doi.org/10.1007/s11095-019-2669-5 DB - PRIME DP - Unbound Medicine ER -